Investing.com -- Catalent (NYSE:CTLT), a contract development and manufacturing organization (CDMO), reported results for Q1 of fiscal 2025 that missed analyst expectations.
The company posted a loss per share of $0.13, significantly worse than the earnings per share (EPS) of $0.03 that analysts expected.
Revenue came in at $1.02 billion, also below the consensus estimate of $1.06 billion.
“Our first quarter fiscal 2025 results reflect the continued momentum in our business and underscore our customers’ continued confidence in Catalent. Financial highlights in the quarter included double-digit year-over-year growth in both non-COVID revenue and adjusted EBITDA, while also delivering positive free cash flow,” said Alessandro Maselli, President and CEO of Catalent.
In its Biologics segment, Catalent saw net revenue rise 3.1% year-over-year to $461 million, though this figure lagged behind the expected $476.2 million.
Meanwhile, Pharmaceuticals&Consumer Health achieved $563 million in net revenue, marking a 5.2% year-over-year increase, and also slightly under the forecast of $563.9 million.
Catalent’s adjusted EBITDA reached $125 million, representing an 8.7% year-over-year gain, but significantly short of the $164.8 million analysts anticipated.
This content was originally published on Investing.com
